Watershed Private Wealth LLC Decreases Stake in Johnson & Johnson $JNJ

Watershed Private Wealth LLC reduced its position in Johnson & Johnson (NYSE:JNJ) by 4.6% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,358 shares of the company’s stock after selling 65 shares during the period. Watershed Private Wealth LLC’s holdings in Johnson & Johnson were worth $207,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. Highline Wealth Partners LLC increased its stake in Johnson & Johnson by 51.8% during the first quarter. Highline Wealth Partners LLC now owns 252 shares of the company’s stock worth $42,000 after acquiring an additional 86 shares during the last quarter. Stone House Investment Management LLC bought a new stake in Johnson & Johnson during the first quarter worth approximately $47,000. 1248 Management LLC bought a new stake in Johnson & Johnson during the first quarter worth approximately $48,000. von Borstel & Associates Inc. bought a new stake in Johnson & Johnson during the first quarter worth approximately $49,000. Finally, Harvest Fund Management Co. Ltd bought a new stake in Johnson & Johnson during the first quarter worth approximately $52,000. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Johnson & Johnson Stock Up 0.5%

Shares of NYSE:JNJ opened at $189.75 on Thursday. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $190.22. The stock has a market cap of $456.98 billion, a P/E ratio of 20.29, a price-to-earnings-growth ratio of 2.41 and a beta of 0.40. The business’s 50 day moving average is $177.49 and its 200 day moving average is $163.37. The company has a quick ratio of 0.76, a current ratio of 1.01 and a debt-to-equity ratio of 0.50.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.68 by $0.09. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.The company had revenue of $23.74 billion for the quarter, compared to analysts’ expectations of $22.85 billion. During the same quarter in the prior year, the firm earned $2.82 earnings per share. Johnson & Johnson’s revenue was up 5.8% compared to the same quarter last year. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. Sell-side analysts predict that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th were paid a $1.30 dividend. The ex-dividend date of this dividend was Tuesday, August 26th. This represents a $5.20 annualized dividend and a yield of 2.7%. Johnson & Johnson’s dividend payout ratio is 55.61%.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on JNJ. Wall Street Zen raised Johnson & Johnson from a “hold” rating to a “buy” rating in a research note on Saturday, September 13th. Barclays boosted their price objective on Johnson & Johnson from $165.00 to $176.00 and gave the stock an “equal weight” rating in a research note on Thursday, July 17th. Weiss Ratings raised Johnson & Johnson from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Wednesday. JPMorgan Chase & Co. upped their target price on Johnson & Johnson from $185.00 to $200.00 and gave the company a “neutral” rating in a research note on Tuesday, September 16th. Finally, HSBC upped their target price on Johnson & Johnson from $188.00 to $210.00 in a research note on Tuesday, September 30th. Two analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and eight have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $189.88.

Insiders Place Their Bets

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the company’s stock in a transaction on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the completion of the sale, the executive vice president owned 178,013 shares in the company, valued at $31,652,491.53. This represents a 24.08% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 0.16% of the stock is currently owned by corporate insiders.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.